ライフサイエンスコーパス: multicenter trial

1 randomized controlled, parallel, superiority multicenter trial.

2 rvastatin 10 versus 80 mg in a double-blind, multicenter trial.

3 ith CR was observed in this large randomized multicenter trial.

4 placebo in a 3-year phase III, double-blind, multicenter trial.

5 mised controlled, parallel-group superiority multicenter trial.

6 symptomatic patients were determined in this multicenter trial.

7 sk patients needs to be confirmed in a large multicenter trial.

8 ted seizure, recently completed a successful multicenter trial.

9 l function can be assessed by telephone in a multicenter trial.

10 1 week in a prospective, placebo-controlled, multicenter trial.

11 plus standard care (n = 77) in an open-label multicenter trial.

12 m positive blood cultures was evaluated in a multicenter trial.

13 andomized, double-blind, placebo-controlled, multicenter trial.

14 ow-up, 27.4 months) in a prospective phase 2 multicenter trial.

15 for the detection of MI in an international, multicenter trial.

16 on for secondary stroke prevention through a multicenter trial.

17 7, 2004, 78 patients were enrolled onto this multicenter trial.

18 nto a randomized, single-blind, prospective, multicenter trial.

19 ipants enrolled in a metabolic substudy of a multicenter trial.

20 ites as part of a previously conducted large multicenter trial.

21 hours in a double-blind, placebo-controlled, multicenter trial.

22 urposes were prospectively recruited in this multicenter trial.

23 600 mg daily) or placebo in a double-blind, multicenter trial.

24 gastrointestinal malignancies in a previous multicenter trial.

25 RST) was a phase II, randomized, open-label, multicenter trial.

26 ality after allogeneic MRD HCT in a phase 3, multicenter trial.

27 ADIAL or femoral approach) was a randomized, multicenter trial.

28 ted to facilitate the use of central IRBs in multicenter trials.

29 it is feasible to implement this approach in multicenter trials.

30 bservations have not been validated in large multicenter trials.

31 ted catheters need to be assessed via large, multicenter trials.

32 t to be validated in prospective randomized, multicenter trials.

33 d as a problem that limits the use of PET in multicenter trials.

34 s and prophylactic fluconazole require large multicenter trials.

35 e foundation for a standardized protocol for multicenter trials.

36 validity and has received extensive study in multicenter trials.

37 an issue in routine clinical processes or in multicenter trials.

38 into an inherent difficulty in establishing multicenter trials.

39 om retinal vein occlusion, also confirmed in multicenter trials.

40 DME and have been confirmed by several large multicenter trials.

41 and able to report their symptomatic AEs in multicenter trials.

42 )F-FDG signal was evaluated in 2 prospective multicenter trials.

43 ive symptoms and call for adequately powered multicenter trials.

44 leukemia is leading to expanded use through multicenter trials.

45 in a relatively short time period in several multicenter trials.

46 probes can be used based on availability in multicenter trials.

47 , SETTING, AND PATIENTS: Randomized clinical multicenter trial (14 centers in 6 countries) between Ma

48 METHODS AND In this prospective, multicenter trial, 169 patients underwent FFR assessment

49 In a prospective, nonrandomized multicenter trial, 45 eligible patients received rituxim

50 In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicati

51 In this multicenter trial, 692 overweight/obese women who were,

52 -small cell lung cancer from the prospective multicenter trials ACRIN 6678 (n = 34) and MK-0646-008 (

53 nfected patients were randomized within a US multicenter trial (ACTG 5071) to receive pegylated-inter

54 This open, randomized, multicenter trial aimed to assess the efficacy and safet

55 ND PARTICIPANTS: A double-blind, randomized, multicenter trial (Aliskiren Quantitative Atherosclerosi

56 prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of

57 We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface a

58 outcomes of these patients in a prospective multicenter trial and investigated whether they develope

59 e stage IIIA NSCLC were enrolled to a German multicenter trial and randomly assigned to receive eithe

60 anced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to re

61 Only a few methods have progressed to multicenter trials and even fewer have become part of cl

62 treatment strategies, various institutions, multicenter trials, and cooperative groups by allowing f

63 Pharmacogenetic studies can be conducted in multicenter trials, and our findings demonstrate that wi

64 ed testing this hypothesis and several large multicenter trials are also underway.

65 Several randomized multicenter trials are currently recruiting patients to

66 Although large, prospective, multicenter trials are lacking, certain factors such as

67 es of neuropsychological function for use in multicenter trials are lacking.

68 apeutic options in well-designed prospective multicenter trials are needed to identify the most effec

69 Large prospective, multicenter trials are now needed to validate the new in

70 Multicenter trials are required with close monitoring of

71 This 3-year, prospective, multicenter trial assessed the safety and efficacy of de

72 A US multicenter trial assessing blunt trauma transports foun

73 A double-blind, randomized, multicenter trial at 362 academic and community hospital

74 AND PARTICIPANTS: Double-blind, randomized, multicenter trial at 97 academic and community hospitals

75 valvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoa

76 This prospective randomized multicenter trial block randomized patients to a restric

77 CE-SSFP and T2-STIR data from 2 recent multicenter trials, CHILL-MI and MITOCARE (n=215), were

78 This multicenter trial compared 1.0% prednisolone sodium phos

79 The present multicenter trial compared 12 weeks of supervised interv

80 This phase 3 randomized, open-label, multicenter trial compared inolimomab vs usual care in a

81 This prospective, randomized, multicenter trial compared primary nitinol stent placeme

82 This placebo-controlled, randomized, multicenter trial compared the effects of MTX plus UDCA

83 This double-blind, multicenter trial compared the efficacy and safety of a

84 No definitive prospective, randomized, multicenter trial compares scleral buckling with pars pl

85 This prospective, randomized, multicenter trial compares the safety and utility of emp

86 We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with

87 GN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel

88 p trial Z0011 was a prospective, randomized, multicenter trial comparing overall survival between pat

89 This first multicenter trial comparing propofol with sevoflurane an

90 ious and nondelirious patients enrolled in a multicenter trial comparing protocolized sedation with p

91 d Tomography Angiography Using 64 Detectors) multicenter trial comparing the diagnostic performance o

92 ent Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and vorico

93 In the absence of large randomized multicenter trials comparing the use of intermittent pne

94 randomized, double-blind, placebo-controlled multicenter trial conducted between February 2007 and Fe

95 tudy was a prospective, randomized phase III multicenter trial conducted by the Children's Cancer Gro

96 S: The EDEN study, a randomized, open-label, multicenter trial conducted from January 2, 2008, throug

97 andomized, double-blind, placebo-controlled, multicenter trial conducted from January 2, 2008, throug

98 NTS: Randomized, noninferiority, open-label, multicenter trial conducted from May 2010 through March

99 In a multicenter trial conducted in the tertiary care setting

100 , significantly more often (p < 0.0001) than multicenter trials conducted by ad hoc groups (n = 89; m

101 Data from three randomized phase III multicenter trials conducted by the Cancer and Leukemia

102 n aged 16-23 years in a phase 2, open-label, multicenter trial, conducted from 2008 to 2011 by the Ad

103 The results from this multicenter trial demonstrated that the treatment of inf

104 cular outflow tract conduits in 2010 after a multicenter trial demonstrating improvements in conduit

105 SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and sa

106 This study represents the first multicenter trial designed to evaluate an imaging approa

107 section and stoma in a randomized controlled multicenter trial, DILALA.

108 ave evaluated the Bonta criteria in a larger multicenter trial encompassing 4 academic institutions.

109 ided the basis for the phase III randomized, multicenter trial ENDEAVOR.

110 Materials and Methods This prospective multicenter trial enrolled 296 carriers of the BRCA muta

111 This randomized, comparator-controlled, multicenter trial enrolled 431 adults from the Universit

112 This prospective, multicenter trial enrolled 480 patients presenting withi

113 randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 year

114 The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients

115 This multicenter trial establishes a GBEF lower limit of norm

116 This randomized phase II multicenter trial evaluated cabozantinib compared with s

117 This prospective phase II multicenter trial evaluated the efficacy and safety of a

118 This multicenter trial evaluated whether lopinavir/ritonavir

119 e prospectively enrolled in an international multicenter trial evaluating (18)F(-) PET/CT, (18)F-FDG

120 ollected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment

121 eport the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of

122 There have been no prospective, multicenter trials evaluating this technology.

123 This multicenter trial examined the efficacy and safety of ox

124 This multicenter trial examined the efficacy, safety, and tol

125 mise but has less clinical validation and no multicenter trial experience.

126 significance of iron deficiency, randomized multicenter trials exploring the use of oral iron supple

127 :1 parallel, randomized, placebo-controlled, multicenter trial for 6 weeks, with an optional 6-week o

128 This largest prospective multicenter trial for adult patients with Burkitt lympho

129 competing for the same patient population as multicenter trials funded by the NIH.

130 ition, in a double-blind, placebo-controlled multicenter trial, galectin-9 levels were measured in th

131 on by all of the major pediatric liver tumor multicenter trial groups.

132 To date, no prospective multicenter trial has evaluated the diagnostic accuracy

133 the past year, the results of several large multicenter trials have been published, clearing the way

134 Multiple randomized, multicenter trials have established the role of the impl

135 Multicenter trials have shown echocardiographic techniqu

136 Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone a

137 andomized, double-blind, placebo-controlled, multicenter trials (identical confirmatory trials were c

138 cerbated COPD), a randomized, noninferiority multicenter trial in 5 Swiss teaching hospitals, enrolli

139 ediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC.

140 conducted a blinded, randomized, controlled, multicenter trial in children undergoing HSCT to determi

141 phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Associ

142 ethods We evaluated IMMU-132 in a single-arm multicenter trial in patients with pretreated metastatic

143 uated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory m

144 ed in a prospective, randomized, controlled, multicenter trial in patients with severe acute liver fa

145 omized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted a

146 In a multicenter trial in Spain, we randomly assigned partici

147 andomized, double-blind, placebo-controlled, multicenter trial in Switzerland between 2005 and 2012.

148 om sample of 385 participants in the DCCT, a multicenter trial in which 1441 subjects aged 13 to 39 y

149 The DECREASE-HF Trial is a multicenter trial in which 306 patients with New York He

150 We performed a prospective noninferiority multicenter trial in which 343 consecutive individuals w

151 We conducted a multicenter trial in which patients with sepsis-associat

152 We performed a multicenter trial in which women with a singleton fetus

153 Well designed multicenter trials in humans, such as those called for i

154 ses, and 69 published single-institution and multicenter trials in which the test performance of SNB

155 A randomized multicenter trial included 212 kidney patients transplan

156 0-Detector Row Computed Tomography (CORE320) multicenter trial included 92 patients (mean age, 63.1 y

157 This prospective, nonrandomized, multicenter trial included adult patients with a standar

158 This prospectively designed, multicenter trial included all adult patients undergoing

159 This randomized (1:1), controlled, multicenter trial included subjects with DME (center poi

160 Ongoing multicenter trials including the Clinical Trials in Orga

161 s were prospectively enrolled as part of the multicenter trial Inflammation and the Host Response to

162 Z0010 was a prospective multicenter trial initiated in 1999 by the American Coll

163 This phase III randomized multicenter trial investigated the benefit of adding ED

164 TIENTS: Post hoc observational analysis of a multicenter trial involving 20,330 patients (age >/=50 y

165 he Dual Antiplatelet Therapy (DAPT) Study, a multicenter trial involving 220 US and international cli

166 We conducted a double-blind, multicenter trial involving 3020 patients with recent sy

167 WASID was a randomized, double-blinded, multicenter trial involving 569 patients with transient

168 andomized, double-blind, placebo-controlled, multicenter trial involving 586 outpatient participants

169 le-blind, placebo-controlled, parallel-group multicenter trial involving 663 US outpatient participan

170 was a prospective, double-blind, controlled, multicenter trial involving hospitalized adult patients

171 repeatability of (18)F-FLT PET as part of a multicenter trial involving patients with high-grade gli

172 In this multicenter trial involving treatment-naive patients wit

173 (TCD) on cGVHD was analyzed in a randomized multicenter trial involving unrelated donor marrow trans

174 We performed an open, international, multicenter trial involving women at 14 weeks 0 days to

175 We performed a multicenter trial involving women without symptoms of st

176 This post hoc study of 3 large multicenter trials involving 2- to 5-year-old children c

177 There is a need for multicenter trials involving defined patient populations

178 andomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute

179 early termination of the trial, and a larger multicenter trial is needed to evaluate the potential be

180 A larger multicenter trial is under way.

181 A large, adequately powered, multicenter trial is warranted to address these findings

182 A multicenter trial is warranted to determine the efficacy

183 standardized and undergo evaluation in large multicenter trials, it is conceivable that a novel marke

184 In this prospective multicenter trial, MR severity was assessed in 103 patie

185 ouble-blind, randomized, placebo-controlled, multicenter trial (NCT00481767), healthy African girls a

186 In this double-blind, multicenter trial (NCT01700192) 1482 subjects (aged >/=1

187 y for the Treatment of Refractory Ascites, a multicenter trial of 109 patients randomized to TIPS or

188 In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disea

189 inal transit was validated using data from a multicenter trial of 320 segmental colectomy patients.

190 e outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to ga

191 This phase II multicenter trial of biweekly 72 hour 9-AC infusion as s

192 In this prospective multicenter trial of chest pain patients without known C

193 lant recipients enrolled in an international multicenter trial of CMV disease treatment (the VICTOR s

194 nciclovir or ganciclovir in an international multicenter trial of CMV disease treatment (the VICTOR s

195 : TAAA I, II, III) enrolled in a prospective multicenter trial of f/b-EVAR.

196 A large multicenter trial of hypothermia in ALF is justified.

197 FINITE) trial was a prospective, randomized, multicenter trial of ICD therapy in 458 patients with no

198 ormance of various cardiac MR sequences in a multicenter trial of patients implanted with an MR-condi

199 ACT-1 is a prospective multicenter trial of patients who have standard surgical

200 We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosph

201 We conducted a randomized, double-blind, multicenter trial of RIV4 (45 mug of recombinant hemaggl

202 Interim data from our ongoing prospective multicenter trial of sentinel node (SN) biopsy indicate

203 A prospective, randomized, controlled, multicenter trial of the efficacy, safety, and tolerabil

204 ipants at 12 U.S. centers participating in a multicenter trial of treatment for acute traumatic brain

205 vated the initiation of a placebo-controlled multicenter trial of Triplex in HCT patients.

206 al, 125 patients were randomly assigned in a multicenter trial of vaccination series.

207 mental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.

208 ER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppur

209 mprove overall survival compared with recent multicenter trials of biochemotherapy or chemotherapy.

210 ical outcome measures and the feasibility of multicenter trials of early dcSSc were confirmed.

211 d individual patient data from 13 randomized multicenter trials of induction and maintenance regimens

212 -MRI methodologies and the focus for initial multicenter trials of MRS.

213 Data were combined from 3 prospective multicenter trials of patients referred for TPVR.

214 Further multicenter trials of this intervention are warranted.

215 Although multicentered trials of lactoferrin use in preterm infan

216 With the emergence of large multicenter trials over the past 20 years, the numbers o

217 clinical trials (P < .001), and by 5.2% for multicenter trials (P < .001).

218 Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to on

219 In this prospective, randomized controlled multicenter trial, patients with primary or recurrent in

220 bo-controlled, double-blind, parallel-group, multicenter trial performed in 26 intensive care units i

221 Materials and Methods In this prospective multicenter trial, PET/CT and clinical data were reviewe

222 ) reduced mortality from septic shock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed

223 This prospective randomized multicenter trial provides evidence that clinical outcom

224 We conducted a prospective, multicenter trial, randomly assigning 190 patients who w

225 This phase III, randomized, multicenter trial showed no difference in survival betwe

226 Our phase II multicenter trial showed that the R-GCVP regimen is an a

227 This multicenter trial showed that trimodality therapy with n

228 This randomized multicenter trial shows that prophylactic application of

229 Our large, multicenter trial shows that the gentamicin-collagen spo

230 idualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into

231 Methods CATCH was a randomized, multicenter trial that investigated tinzaparin 175 IU/kg

232 nd Late Loss Optimization) is a prospective, multicenter trial that randomized 182 patients with lesi

233 ified randomized trials, 4 were high-quality multicenter trials that involved a total of 17 133 patie

234 antidepressants in pediatric patients and 1 multicenter trial (the Treatment for Adolescents With De

235 vedilol was examined in a placebo-controlled multicenter trial, the Carvedilol Post-Infarct Survival

236 In a randomized, double-blind, multicenter trial, the efficacy and safety of prophylact

237 pective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab mon

238 rking Group Recovery Study was a prospective multicenter trial to assess the incidence of myocardial

239 andomized, placebo-controlled, double-blind, multicenter trial to assess the safety and efficacy of t

240 andomized, double-blind, placebo-controlled, multicenter trial to assess the safety, immunogenicity,

241 phylococcus aureus (MRSA) collected during a multicenter trial to determine if three negative culture

242 We conducted a double-blind, randomized multicenter trial to determine whether the addition of m

243 IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety,

244 opharmaceutical for Myocardial Imaging) is a multicenter trial to evaluate the accuracy, outcomes, an

245 (1) PANCREOX was a phase III multicenter trial to evaluate the benefit of FU and oxal

246 tcomes, we conducted a phase 2, prospective, multicenter trial to test the efficacy of the addition o

247 nce in Dialysis trial, a 6-month randomized, multicenter trial to test whether a simple, personalized

248 t steps in clinical development will require multicenter trials to establish adoptive immunotherapy a

249 wed combined data from 3 ongoing prospective multicenter trials to evaluate the experience with IE am

250 It will be necessary to design large multicenter trials to overcome the expected improvements

251 In this multicenter trial, treatment with 20 mg/d of rimonabant

252 andomized, double-blind, placebo-controlled, multicenter trial using a 2x2 factorial design in which

253 Although a recent multicenter trial using this technique demonstrated enco

254 Samples were collected in a prospective, multicenter trial validating a gene expression classifie

255 SLND failure rate in the setting of a large multicenter trial, validating the incorporation of SLND

256 A phase II multicenter trial was conducted to evaluate the efficacy

257 placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy

258 A prospective multicenter trial was conducted to evaluate the safety a

259 This phase 3, double-masked, multicenter trial was designed to randomize 368 patients

260 ation is safe and efficacious, a randomized, multicenter trial was performed in 12 pediatric kidney t

261 A secondary analysis of a randomized multicenter trial was performed in order to determine th

262 This prospective randomized multicenter trial was performed to assess the potential

263 A phase 2 multicenter trial was performed to evaluate single-agent

264 One sham controlled multicenter trial was published this year.

265 The multicenter trial was the only individual trial to show

266 on, a phase I-II, open-label, nonrandomized, multicenter trial was therefore designed using (99m)Tc-s

267 A phase II, multicenter trial was undertaken to assess the immunogen

268 MetaPlus study, a randomized, double-blind, multicenter trial, was conducted from February 2010 thro

269 e DIABOLO study, a randomized, double-blind, multicenter trial, was conducted from October 2011 throu

270 In this multicenter trial we compared initial therapy involving

271 In this multicenter trial we established the clinical performanc

272 andomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infect

273 In this multicenter trial, we enrolled 240 patients at high risk

274 In this 3-year open-label, multicenter trial, we evaluated 708 patients who had sub

275 In this phase 2 multicenter trial, we evaluated the activity of bortezom

276 In this double-blind, multicenter trial, we evaluated the efficacy and safety

277 In this phase 2 multicenter trial, we evaluated the efficacy of the comb

278 In a double-blind, multicenter trial, we randomized 615 hyperlipidemic, pos

279 In this multicenter trial, we randomly assigned 131 patients who

280 In a multicenter trial, we randomly assigned 270 critically i

281 In this randomized, prospective, open-label, multicenter trial, we randomly assigned 600 patients wit

282 In this multicenter trial, we randomly assigned 706 patients who

283 In an open-label, controlled, multicenter trial, we randomly assigned 708 patients wit

284 In this double-blind, multicenter trial, we randomly assigned 750 women, in a

285 In a double-blind, multicenter trial, we randomly assigned adult patients w

286 In this multicenter trial, we randomly assigned nontunneled cent

287 In this multicenter trial, we randomly assigned patients 40 to 7

288 In this multicenter trial, we randomly assigned transplant recip

289 years old who participated in a prospective multicenter trial were divided into a training set (n =

290 5, 54.9% of all clinical trials and 55.6% of multicenter trials were NIH funded.

291 nfarction Evaluation) trial is a prospective multicenter trial which enrolled 728 clinically stable s

292 This study included patients enrolled in 3 multicenter trials, who received a leadless cardiac pace

293 randomized, placebo-controlled, double-blind multicenter trial will be performed for which 980 patien

294 he embedding of quantitative CT (QCT) into a multicenter trial with a variety of scanner makes and mo

295 We designed and implemented a multicenter trial with an adaptive, two-stage, bias-adju

296 In this open-label, multicenter trial with crossover design, we randomly ass

297 A phase III multicenter trial with patient-specific dosing is planne

298 uble-blind, double-dummy, active-controlled, multicenter trial with the objective of evaluating the s

299 m a small number of high-volume centers, but multicenter trials with less experienced surgeons have s

300 tudy provides a strong rationale for further multicenter trials with sufficient power to identify dif